Related Experiment Videos
Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous
P Griffiths1, R Campbell, P Robinson
1Department of Psychology, University of Stirling, UK.
Insights
Early and continuous treatment for phenylketonuria (PKU) in children appears to prevent executive dysfunction. Neuropsychological tests showed no differences between treated PKU children and controls, supporting current dietary guidelines.
Area of Science:
- Neuroscience
- Pediatrics
- Metabolic Disorders
Background:
- Phenylketonuria (PKU) is a metabolic disorder requiring early dietary intervention.
- Concerns persist regarding potential long-term cognitive deficits, specifically executive dysfunction, in treated individuals.
- The executive dysfunction hypothesis suggests impairments in cognitive control processes in PKU.
Purpose of the Study:
- To investigate the executive dysfunction hypothesis in children with classical PKU.
- To assess the impact of early and continuous treatment on executive functions.
- To determine if phenylalanine levels correlate with neuropsychological test performance.
Main Methods:
- Utilized the one-back and two-back versions of the Continuous Performance Test (CPT).
- Compared 11 non-retarded, school-age children with classical PKU (early and continuously treated) to matched healthy controls.
- Analyzed historical and concurrent plasma phenylalanine concentrations.
Main Results:
- Treated PKU children performed indistinguishably from controls on CPT measures.
- Neuropsychological performance was not predicted by phenylalanine concentrations.
- Mean lifetime phenylalanine levels in subjects were within recommended UK dietary optima.
Conclusions:
- The study provides evidence against the executive dysfunction hypothesis in early and continuously treated PKU.
- Findings support the efficacy of current UK dietary management policies for PKU.
- Early intervention appears to mitigate cognitive deficits associated with PKU.
Abstract:
The executive dysfunction hypothesis in treated phenylketonuria was investigated by means of the one-back and two-back versions of the continuous performance test. Eleven non-retarded, primary school-age children with classical phenylketonuria who had been treated early and continuously were indistinguishable from healthy, matched controls on the measures and test performance was not predicted by historical or concurrent plasma phenylalanine concentrations. Mean lifetime phenylalanine concentrations for the phenylketonuric subjects were within ranges currently recommended as dietary optima in the United Kingdom. The negative neuropsychological test findings add weight to the rationale for this policy.